Fulvestrant isa selective estrogen receptor degrader (SERD) and a high affinity estrogen receptor antagonist. It is used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. 
Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. 
Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. 
 C.K.Osborne, et al, Br. J. Cancer, 2004, 90(Suppl. 1), pp S2-S6.
 J.F.Robertson, et al, Clin. Pharmacokinet., 2004, 43(8), pp 529-538.
 J.D.Croxtall, et al, Drugs, 2011, 71(3), pp 363-382.
Not classified as a hazardous substance or mixture
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.